Frequencies of autoantibodies detected by LB and IP assays across EULAR/ACR myositis subtypes
| No of subjects (%) | DM 36 (32) | ADM 4 (4) | JDM 3 (3) | PM 52 (47) | IBM 16 (14) | Total 110 (100) | Controls 60 | ||||||
| LB | IP | LB | IP | LB | IP | LB | IP | LB | IP | LB | IP | LB | |
| Anti-Jo1 | 7 | 4 | 1 | 1 | 1 | 1 | 9 | 6 | 0 | 0 | 18 | 12 | 0 |
| Anti-PL7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Anti-PL12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Anti-Ej | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anti-Oj | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Anti-SRP | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 3 | 4 | 0 |
| Anti-PmScl (75/100kD) | 1 | 2 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 3 | 5 | 0 |
| Anti-Ku | 1 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 4 | 3 | 1 |
| Anti-SAE1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 4 | 3 | 0 |
| Anti-NXP2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Anti-MDA5 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Anti-TIFγ | 7 | 11 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 8 | 12 | 0 |
| Anti-Mi2 (α/β) | 2 | 1 | 0 | 0 | 0 | 0 | 5 | 0 | 1 | 1 | 8 | 2 | 1 |
| Any autoantibody | 21 | 21 | 1 | 2 | 2 | 3 | 22 | 18 | 2 | 1 | 48 | 45 | 3 |
ACR, American College of Rheumatology; ADM, amyopathic dermatomyositis; DM, dermatomyositis; EULAR, European League Against Rheumatism; IBM, inclusion body myositis; IP, immunoprecipitation; JDM, juvenile dermatomyositis; LB, line blot; PM, polymyositis.